Share Name Share Symbol Market Type Share ISIN Share Description
Silence Therapeutics Plc LSE:SLN London Ordinary Share GB00B9GTXM62 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  16.00 5.26% 320.00 312.00 324.00 330.00 304.00 304.00 2,325,145 16:35:23
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -20.5 -26.2 - 250

Silence Therapeutics Share Discussion Threads

Showing 50276 to 50300 of 51475 messages
Chat Pages: Latest  2023  2022  2021  2020  2019  2018  2017  2016  2015  2014  2013  2012  Older
DateSubjectAuthorDiscuss
03/11/2017
08:50
Seems like an expedient time to add to the SIPP holding
volsung
30/10/2017
23:59
1gw hope you are right, it's simmering right now and the resistance to bounce a little after the previous sessions falls was nice to see. Wonder if there'll be a bit more news between now and the CMD?
ukeagle2aus
30/10/2017
15:35
Looks like a bit of interest today. Arrowhead bounced back at the end of last week after a brief biotech selloff I think. Only 2 weeks to go to the capital markets day. What price a decent rise ahead of that?
1gw
20/10/2017
15:12
Never any harm in taking a profit 1gw - I sold half mine at £1.70 - how daft was that in retrospect but felt the holding was becoming too large a share of my portfolio. SLN has now doubled over the year and trebled from its lows. Hoping for something similar with IRON - like SLN one of my largest holdings and like SLN been one of the dogs in my portfolio for a number of years. Hoping for a similar turnaround from dud to star!
callumross
20/10/2017
14:58
And sold a few more just now. A bit less than 1/4 of my holding gone today.
1gw
20/10/2017
08:13
I've joined the profit-taking and sold some this morning. I think the prospects are good leading up to the capital markets day, but it was getting a bit uncomfortable watching the volatility given it had become such a big weight in my portfolio. Even after this morning's sale it is still marginally the biggest holding I have, but now very close in size to a couple of other holdings.
1gw
18/10/2017
12:17
Ah, the predictable profit taking on the news. Pity the poor sod who only got 202.9p for his 1500 shares when the price dropped before the order book was rebuilt. Always the danger with setting an automatic stop loss.
callumross
18/10/2017
06:15
Align Research‏ @AlignResearch 3s3 seconds ago More Continued good news for Silence Therapeutics shareholders - https://www.investegate.co.uk/silence-therapeutics--sln-/rns/further-us-patents-granted/201710180700038740T/ … Only ncreases pressure on Alnylam to do a deal. #SLN
richie666
17/10/2017
02:21
Yes thanks from me as well 1gw. I thought he came across like the cat that knew he had a fridge full of cream. I also felt like he would prefer it if Silence remained independent and became a bigger/leading player in its own right? He certainly teed up the capital markets day with plenty of teasing and his assessment of the new chair couldn't have been scripted better to instill a lot of confidence amongst the viewing audience. Interesting month ahead, little leap in the price yesterday, but I wouldn't be surprised to see a bit of profit taking ahead of more steady ticks up over the next couple of weeks? GLA
ukeagle2aus
16/10/2017
18:21
Thanks for the link 1gw. Very interesting. Holding tight to my remaining shares having regrettably sold half at the £1.70 level.
callumross
16/10/2017
17:34
Ali doing a 12-minute slot on Proactive Investors. Thanks to jupiternmars on the LSE board for finding the link. In this interview he is starting to tease the contents of the capital markets day. He also talks at some length about the patents and covers the new chair's background (including reference to the counterbids for Dimension). He holds out the hope of more releases on the science and the medicines and fewer on the patents in the year to come. hTtps://www.youtube.com/watch?v=pQJi-PwC_t4
1gw
16/10/2017
15:15
Or perhaps she is being lined up for an executive role after the Dimension sale goes through?
1gw
16/10/2017
15:14
Looks to be some very interesting background on the new chair that didn't make it into this morning's rns. She is CEO of Dimension Therapeutics. On 25th August Dimension announced an all-stock agreement to sell itself to Regenxbio at an implied price of $3.41 per share. Then on 18th September Dimension announced that it had received an unsolicited offer from Ultragenyx to buy the company for $5.50 per share cash. After apparently entering into negotiations over this potentially "superior proposal" Dimension announced on 2nd October that it had decided the Ultragenyx offer was a "superior proposal" (a defined term in the original merger agreement with Regenxbio) and that the offer was now $6.00 cash per share. For most of 2017, Dimension appears to have traded at under $2. Can she pull off the same trick here? hTtp://investors.dimensiontx.com/phoenix.zhtml?c=254192&p=irol-news&nyo=0
1gw
16/10/2017
09:22
If this was all planned, I have to admire the way they've done it. Really going back to the Arrowhead stake purchase they've managed to keep the excitement building through the year with the repeated news and commentary around patents, the court case, the "year of RNAI" and now a new and impressive-sounding chair. And now it's only just over 4 weeks to the capital markets day, so that should soon be in the frame as well in terms of speculation about what might be revealed.
1gw
16/10/2017
09:18
Unless it's just the new chair taking a stake...
1gw
16/10/2017
09:09
That type of buying this morn is informed buying in my experience. Perhaps Alnylam about to make a move. If Griffo was paying 2 squid my guess they go towards 300p
richie666
16/10/2017
08:24
Looks like someone likes this morning's rns.
1gw
12/10/2017
00:09
Interesting indeed, I wonder if ALNY will rethink their course of action in Europe now? You've also got to hand it he MM'S, small volumes I admit over the past few days, but price being held down, despite trades going in consistently above the offer price? Still, a slow steady rise for a month or two, would be a nice base before any potential bid.
ukeagle2aus
11/10/2017
07:32
They're certainly trying to hammer home the point on the patents and Alny. This morning's rns is I think the first comment Silence has made on Patisiran since the recent news from Alny on its progress.
1gw
11/10/2017
07:25
The pieces continue to be put into place ref the sale of the company imo. News this morning layering the icing on the cake.
richie666
05/10/2017
11:16
Except that Griffiths has already declared above 29% so hasn't got another declaration to make on the upside unless he wants to bid for the company himself. Keith has got capacity to buy more and I agree he would be likely to be made an insider and asked to commit to support any deal that the board wanted to recommend. So I took their latest declarations (as of 20th September) as evidence that a deal wasn't close to conclusion at that time. The problem for your theory though is that the absence of buying is not a "stopping time" - it can only be disproved. Keith went through 19% in May 2016 I think, and was only shown "still" to be buying 16 or so months later when he declared going through 20% in September 2017.
1gw
05/10/2017
10:41
There is also the possibility of all paper merger with ARWR. Dont discount that.Clue here will be no more buying by Griffiths and related parties. With his stake size he will no doubt be made inside on any deal.
richie666
05/10/2017
08:52
I suppose big pharma might be a more equal match, in terms of legal resources for a patent battle, for Alny than Silence would be by itself. So if Silence does have a reasonable (but not cast iron) case against Alny then it might be more deliverable with big pharma backing and hence more valuable on a risked basis to big pharma than to Silence. I wonder if Capital Markets day is as much about setting out Silence's stall to potential bidders, as it is about informing its own shareholders and the wider investment community about the company. I note that "media" feature in the target audience: "a Capital Markets event for investors, analysts and media".
1gw
05/10/2017
05:40
Well if RNAi is really now taking off as a therapy then big pharma could be looking for further access too
rogen83
05/10/2017
01:31
Hope you are on the money R83 I keep taking a look the morning after (from Aus) and I half expect my golden touch to have a reverse effect. This time though added my all in at 197, so nice to see a little nudge up from there. Will ALNY bite the bullet and make a bid? Or will their stubborn CEO stick to his guns and spend the buy out money on defending his corner instead? Ideally a bit of steady ramp in the price for now and then a bid at the top end of the bid range. Can we get that lucky? GLA
ukeagle2aus
Chat Pages: Latest  2023  2022  2021  2020  2019  2018  2017  2016  2015  2014  2013  2012  Older
Your Recent History
LSE
SLN
Silence Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200118 23:32:00